Cancer Genetics

Scope & Guideline

Unlocking the Secrets of Cancer Through Genetics

Introduction

Welcome to the Cancer Genetics information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Cancer Genetics, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN2210-7762
PublisherELSEVIER SCIENCE INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2011 to 2024
AbbreviationCANCER GENET-NY / Cancer Genet.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressSTE 800, 230 PARK AVE, NEW YORK, NY 10169

Aims and Scopes

The journal 'Cancer Genetics' focuses on the intersection of genetic research and cancer biology, providing a platform for the dissemination of findings that enhance our understanding of cancer genetics and its implications for diagnosis, treatment, and patient management.
  1. Genetic Mechanisms of Cancer:
    The journal emphasizes studies that elucidate the genetic alterations associated with various cancers, including mutations, copy number variations, and chromosomal rearrangements.
  2. Clinical Applications of Genetic Testing:
    Research published in the journal often explores the application of genetic testing for cancer risk assessment, diagnosis, and treatment decisions, including the use of targeted therapies and personalized medicine.
  3. Biomarker Discovery and Validation:
    The journal highlights the identification and validation of genetic and epigenetic biomarkers that can predict cancer progression, treatment response, and patient outcomes.
  4. Molecular Pathology and Tumor Genomics:
    A significant focus is placed on the integration of molecular pathology techniques with genomic sequencing to improve the understanding of tumor heterogeneity and therapeutic resistance.
  5. Translational Research and Therapeutics:
    The journal supports translational research that bridges laboratory findings with clinical practice, particularly studies that investigate novel therapeutic strategies and drug development.
The journal 'Cancer Genetics' has adapted to the evolving landscape of cancer research, with several themes emerging as prominent areas of interest in recent publications.
  1. Liquid Biopsies and ctDNA:
    There is a growing emphasis on the use of liquid biopsies and circulating tumor DNA (ctDNA) as non-invasive tools for cancer detection, monitoring treatment response, and predicting relapse.
  2. Genetic Profiling and Personalized Medicine:
    Research focusing on comprehensive genetic profiling of tumors to inform personalized treatment strategies is on the rise, highlighting the shift towards tailored therapies based on individual genetic makeup.
  3. Functional Genomics and Gene Editing:
    Emerging methodologies such as CRISPR and other gene editing technologies are increasingly featured, showcasing their potential in understanding cancer biology and developing novel therapeutic approaches.
  4. Long Non-Coding RNAs and Epigenetic Regulation:
    The investigation of long non-coding RNAs and their role in cancer development and progression is gaining traction, reflecting a broader interest in epigenetic factors that influence gene expression in malignancies.
  5. Integration of Multi-Omics Data:
    There is a trend towards the integration of multi-omics approaches (genomics, transcriptomics, proteomics) to provide a more comprehensive understanding of cancer biology and treatment responses.

Declining or Waning

While 'Cancer Genetics' has seen significant advancements in various areas of cancer research, certain themes have begun to decline in prominence over recent years, indicating a shift in research focus and interest.
  1. Traditional Cytogenetics:
    Research centered around traditional cytogenetic techniques such as karyotyping is appearing less frequently, as newer genomic technologies like next-generation sequencing (NGS) become more prevalent.
  2. General Cancer Epidemiology:
    There is a noticeable decline in studies focusing solely on cancer epidemiology without a genetic component, as the field increasingly prioritizes genetic and molecular factors in cancer research.
  3. Basic Laboratory Research:
    Papers focusing solely on basic laboratory techniques without direct applications to clinical practice or genetic implications are becoming less common, as the journal pivots toward more clinically relevant research.
  4. Single Gene Studies:
    Studies investigating the role of single genes in cancer without considering the broader context of genomic interactions and networks are waning, reflecting a trend towards more integrative genomic approaches.

Similar Journals

Annual Review of Cancer Biology

Navigating the Evolving Landscape of Cancer Biology
Publisher: ANNUAL REVIEWSISSN: 2472-3428Frequency: 1 issue/year

Annual Review of Cancer Biology is a pivotal journal published by Annual Reviews, specializing in the rapidly evolving field of cancer research. With an impact factor positioned in the distinguished Q1 quartile of Cancer Research, Cell Biology, and Oncology categories, this journal ensures that it showcases the highest quality of scholarly contributions. Indexed in Scopus, it ranks among the top in its fields, reflecting its strong influence and relevance, with remarkable percentiles indicating its esteemed position within the research community. Although not an open-access journal, it provides a comprehensive platform for advancing the frontiers of cancer biology through rigorously curated reviews, highlighting key developments, breakthroughs, and future directions that inform both academia and clinical applications. As a valuable resource for researchers, professionals, and students, the Annual Review of Cancer Biology serves as an essential guide for understanding and addressing the complexities of cancer biology today.

GENES CHROMOSOMES & CANCER

Bridging Genetics and Cancer for a Healthier Tomorrow.
Publisher: WILEYISSN: 1045-2257Frequency: 12 issues/year

GENES CHROMOSOMES & CANCER, published by Wiley, is a premier journal in the intertwined fields of cancer research and genetics. With an ISSN of 1045-2257 and an e-ISSN of 1098-2264, this journal has been a significant outlet for innovative research since its inception in 1989, continuing through to 2024. Positioned in the Q2 quartile of both Cancer Research and Genetics categories in 2023, it reflects a strong impact in the scientific community, as evidenced by its Scopus rankings—99th in Genetics and 83rd in Cancer Research. Though it does not provide open access options, GENES CHROMOSOMES & CANCER offers valuable insights that foster collaboration and discovery among researchers, professionals, and students dedicated to understanding the genetic underpinnings of cancer. With its reputable standing, this journal is a vital resource for those aspiring to contribute meaningful advancements in cancer genetics and therapeutic interventions.

CANCER SCIENCE

Leading the charge in innovative cancer treatment solutions.
Publisher: WILEYISSN: 1347-9032Frequency: 12 issues/year

Cancer Science, an esteemed journal published by Wiley, stands at the forefront of oncology research, boasting an impressive impact factor and a classification in the Q1 category for its contributions in Cancer Research, Medicine, and Oncology as of 2023. Since its inception in 2003 and transitioning to an Open Access model in 2014, the journal has facilitated global dissemination of critical research findings, ensuring that vital information remains accessible to researchers, clinicians, and students alike. With its comprehensive scope covering cutting-edge discoveries in cancer biochemistry, genetics, and molecular biology, Cancer Science is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of cancer. The journal, located at 111 River St, Hoboken, NJ, is an essential resource for anyone dedicated to improving treatment outcomes and pushing the boundaries of cancer research.

Human Genomics

Pioneering Discoveries in Genomics and Medicine
Publisher: BMCISSN: 1473-9542Frequency: 1 issue/year

Human Genomics, published by BMC, is a leading open-access journal dedicated to advancing the field of genomics and its applications in health and disease. Since its inception in 2003, the journal has provided a vital platform for researchers to disseminate groundbreaking findings related to genetic research, contributing significantly to areas such as Drug Discovery, Genetics, Molecular Biology, and Molecular Medicine, as reflected in its Q1 and Q2 quartile rankings throughout 2023. With an ISSN of 1473-9542 and an E-ISSN of 1479-7364, Human Genomics not only delivers high-quality, peer-reviewed research but also ensures accessibility to a broader audience, empowering professionals, students, and academics to stay at the forefront of genomic science. Through its rigorous editorial standards and impactful publications, the journal fosters a collaborative environment for innovative research across the globe from its base in the United Kingdom. By promoting open access since its launch, Human Genomics continues to enhance the visibility and impact of genetic studies, making it an essential resource for anyone involved in the rapidly evolving field of human genomics.

INTERNATIONAL JOURNAL OF HUMAN GENETICS

Bridging Gaps in Human Genetic Understanding
Publisher: KAMLA-RAJ ENTERPRISESISSN: 0972-3757Frequency: 4 issues/year

INTERNATIONAL JOURNAL OF HUMAN GENETICS is a distinguished publication dedicated to advancing knowledge in the fields of genetics and molecular biology. Published by KAMLA-RAJ ENTERPRISES, this journal explores critical developments and research findings from 2008 to 2016, though its coverage in Scopus has since been discontinued. With an ISSN of 0972-3757 and an E-ISSN of 2456-6330, the journal aimed to foster scholarly dialogue and serve as a resource for researchers, professionals, and students engaged in human genetics. While the journal holds a modest ranking in categories such as Biochemistry and Genetics, it remains a vital source for exploring niche topics within the realm of human genetics. Researchers interested in genetic screening, gene therapy, and clinical genetics will find valuable insights herein. Despite its pause in indexing, the journal continues to contribute to the academic discourse by disseminating critical research that bridges gaps in understanding human genetics.

HUMAN GENETICS

Driving innovation in clinical genetics.
Publisher: SPRINGERISSN: 0340-6717Frequency: 12 issues/year

HUMAN GENETICS, published by SPRINGER, stands as a cornerstone journal in the field of genetics, offering a wealth of research insights since its inception in 1964. Hailing from Germany, this esteemed journal boasts an impressive Q1 ranking in both Genetics and Clinical Genetics, marking it among the top quartile of journals in these categories for 2023. With a notable Scopus rank of #7 in Clinical Genetics and a percentile ranking of 93, HUMAN GENETICS attracts significant attention from researchers and professionals dedicated to advancing our understanding of genetic influences on human health and disease. Although it does not currently offer Open Access options, the journal provides a critical platform for scholarly communication, aimed at disseminating groundbreaking findings in genetics and biotechnology. As the field evolves, HUMAN GENETICS continues to play an instrumental role in bridging the gap between laboratory research and clinical application, making it an essential resource for students and seasoned researchers alike.

CANCER AND METASTASIS REVIEWS

Fostering Innovation in Cancer Treatment Strategies
Publisher: SPRINGERISSN: 0167-7659Frequency: 4 issues/year

Cancer and Metastasis Reviews, published by Springer, is a leading journal in the field of oncology and cancer research. With an impressive impact factor placing it in the Q1 category for both Cancer Research and Oncology as of 2023, this journal is ranked 29th out of 404 in Medicine, Oncology, and 22nd out of 230 in Biochemistry, Genetics, and Molecular Biology, reflecting its significant influence and prestige in the academic community. Established in 1982, the journal covers a wide spectrum of topics related to the mechanisms of cancer progression and metastasis, making it an essential resource for researchers, healthcare professionals, and students dedicated to understanding and tackling cancer. Although the journal does not provide open access options, the impactful research it publishes contributes to advances in therapeutic strategies and enhances the collective knowledge surrounding cancer pathophysiology. With research converging from 1982 to 2024, Cancer and Metastasis Reviews continues to be a vital platform for disseminating high-quality scientific information in the ever-evolving landscape of cancer research.

Annual Review of Pathology-Mechanisms of Disease

Illuminating the Pathways of Disease Understanding
Publisher: ANNUAL REVIEWSISSN: 1553-4006Frequency: 1 issue/year

Annual Review of Pathology: Mechanisms of Disease is a premier scholarly journal published by ANNUAL REVIEWS that systematically reviews significant advancements in the field of pathology and the mechanisms underpinning various diseases. With an ISSN of 1553-4006 and an E-ISSN of 1553-4014, the journal has established its importance within the academic community, evidenced by its prestigious Q1 rankings in several categories including medicine, pathology, forensic medicine, and plant science for 2023. Notably, it ranks #1 out of 208 in the pathology and forensic medicine category, placing it in the 99th percentile according to Scopus metrics. Although not an open-access journal, it offers crucial insights to researchers, professionals, and students alike by providing a comprehensive understanding of pathophysiological concepts and emerging trends. The journal continues to be an essential resource for those dedicated to advancing research and practical applications in disease mechanisms.

Oncogenesis

Fostering global collaboration in cancer discovery.
Publisher: SPRINGERNATUREISSN: 2157-9024Frequency: 1 issue/year

Oncogenesis is a prestigious open access journal, published by SpringerNature, dedicated to advancing our understanding of cancer biology and molecular mechanisms of oncogenesis. Since its inception in 2012, this journal has quickly established itself as a leading platform for innovative research, being ranked in the Q1 quartile in both Cancer Research and Molecular Biology categories for 2023. With an admirable impact factor that reflects its exceptional quality, Oncogenesis is indexed in Scopus, holding notable rankings in both Molecular Biology and Cancer Research, placing in the 87th and 83rd percentile respectively. The journal not only facilitates the dissemination of groundbreaking research but also encourages collaboration among scientists and healthcare professionals across the globe. By offering open access to its articles, Oncogenesis ensures that vital findings reach a diverse audience, fostering a deeper dialogue and understanding in the fight against cancer. Based in the United States but with a global reach, the journal remains committed to publishing high-impact studies that contribute to the advancement of knowledge in the realms of oncology, biochemistry, and genetics.

Cancer Discovery

Fostering Dialogue to Revolutionize Cancer Research
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2159-8274Frequency: 12 issues/year

Cancer Discovery, published by the American Association for Cancer Research, stands as a vital resource in the oncological research community, renowned for its commitment to disseminating groundbreaking studies and innovative findings in cancer biology, prevention, diagnostics, and treatment. With a significant impact factor reflecting its esteemed position, this journal facilitates open discussions and collaborations, striving to bridge the gap between experimental and clinical research. The journal, which has been active since 2011, is classified as a Q1 publication in 2023, underscoring its influence and authority in the realm of Oncology. By providing a platform for rigorous peer-reviewed articles, Cancer Discovery aims to advance our understanding of cancer and enhance therapeutic strategies, making it an indispensable tool for researchers, professionals, and students eager to stay at the forefront of cancer research.